Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma

(2011) R.-O. Casasnovas et al.   BLOOD

Role of Functional Imaging in the Management of Lymphoma

(2011) Bruce D. Cheson   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma

(2010) Pier Luigi Zinzani et al.   CANCER

Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

(2010) Craig H. Moskowitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Interim18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?

(2010) Michel Meignan et al.   LEUKEMIA & LYMPHOMA

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

(2009) S. J. Horning et al.   BLOOD

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

(2009) U. Vitolo et al.   HAEMATOLOGICA

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review

(2009) Teruhiko Terasawa et al.   JOURNAL OF CLINICAL ONCOLOGY

The Case Against Heavy PETing

(2009) Bruce Cheson   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy

(2009) E. Itti et al.   JOURNAL OF NUCLEAR MEDICINE

PET/CT for Therapy Response Assessment in Lymphoma

(2009) M. Hutchings et al.   JOURNAL OF NUCLEAR MEDICINE

Report on the First International Workshop on interim-PET scan in lymphoma

(2009) Michel Meignan et al.   LEUKEMIA & LYMPHOMA

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

(2008) H. S. Han et al.   ANNALS OF ONCOLOGY

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

(2008) A. Martin et al.   HAEMATOLOGICA

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY